Anavex Life Sciences Corp. (LON:0HFR)

Market Cap	728.76M
Revenue (ttm)	n/a
Net Income (ttm)	-36.49M
Shares Out	n/a
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	12.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,763
Average Volume	4,185
Open	11.11
Previous Close	11.05
Day's Range	10.92 - 11.18
52-Week Range	4.67 - 14.45
Beta	0.67
RSI	74.14
Earnings Date	Aug 12, 2025

About Anavex Life Sciences

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept stud...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2004
• Employees: 42
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HFR

Financial Performance

Financial numbers in USD